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Following significant injury, the heart undergoes induced compensation and gradually deteriorates towards
impending heart failure. Current therapy slows but does not halt the resultant adverse remodeling. Stem cell
therapy, however, has the potential to regenerate or repair infarcted heart tissue and therefore is a promising
therapeutic strategy undergoing intensive investigation. Due to the wide range of stem cells investigated, it is
difficult to navigate this field. This review aims to summarize the main types of stem cells (both of cardiac and
extra-cardiac origin) that possess promising therapeutic potential. Particular focus is placed on clinical trials
supporting this therapeutic strategy.
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Myocardial infarction (MI) remains a leading cause of
death and disability worldwide. In the United States
alone, approximately 1 million cases of MI occur annu-
ally (Roger et al. 2011). The implementation of cardio-
vascular prevention strategies continues to reduce the
incidence of MI. Concurrently, however, evolution of
pharmacological approaches and coronary reperfusion
interventions has led to an increased post-MI survival
rate, which in turn has raised MI disease morbidity. Pre-
vious estimates indicate that approximately 90–95% of
patients survive their first MI (Rosamond et al. 2012),
contributing to a current “epidemic” of heart failure and
imposing an enormous health burden on individuals and
the community.
After MI, local cardiac compensatory mechanisms are
activated giving rise to a vicious cycle of cardiac metabolic
insufficiency, leading to heart failure and potentially sud-
den death (Orn et al. 2007). Timely reperfusion together
with optimal drug and device-based interventions has im-
proved MI management by reducing the initial burden of
injury and slowing progression of resultant adverse re-
modeling (White et al. 2005). Nevertheless, no current
therapy is able to reverse the inexorable decline in cardiac
function. Therefore, new strategies investigating cardiac
regeneration have demanded considerable interest. These* Correspondence: james.chong@sydney.edu.au
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reproduction in any medium, provided the originvolve either 1) the implantation of stem cells or their de-
rivatives directly into the heart or 2) the activation of en-
dogenous cardiac repair mechanisms in order to replace
damaged cardiomyocytes and promote vascular recon-
struction (Laflamme and Murry 2011).
This review provides physicians with a concise over-
view of the major types of stem cells, both from cardiac
or extra-cardiac origins, being investigated for post-MI
treatment. For further detail and information on en-
dogenous cardiac regeneration, the interested reader is
directed to the following detailed reviews (Laflamme and
Murry 2011; Choi and Poss 2012; Rasmussen et al.
2011).Extra-cardiac stem cells
Skeletal myoblasts
Skeletal myoblasts (SKM) are the progenitor cells of skel-
etal muscle. Initial observations that SKMs could be har-
vested from an autologous origin, easily expanded ex vivo
and undergo spontaneous differentiation into contractile
muscle sparked interest in SKMs for cardiac myoplasty
(Taylor et al. 1998). Early uncontrolled clinical studies re-
ported that SKMs could engraft in the injured heart with
remarkable efficiency and enable significant improvement
in cardiac function (Menasche et al. 2003). These findings
were not reproduced in a subsequent prospective random-
ized placebo-controlled trial (Menasche et al. 2008), where
97 participants with severe left ventricular (LV) dysfunc-
tion underwent transepicardial autologous SKM injection
at the time of coronary artery bypass grafting. Six monthsis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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was found when compared to placebo. Importantly, a high
prevalence of ventricular tachyarrhythmias was observed
leading to premature discontinuation of the trial. Similar
results were observed in the SEISMIC trial which used
transendocardial injection of autologous SKMs (Veltman
et al. 2008). A follow-up study conducted four years later
reported no significant change in LV function compared
to the placebo group.
The general consensus amongst clinicians now is that
SKMs do not electrically couple to host cardiomyocytes
(Leobon et al. 2003). Notably, it is now understood that
the gap-junction protein, connexin 43, can augment
intracellular coupling of cardiomyocytes and confers a
protective effect against ventricular tachyarrhythmias
following cell transplantation (Roell et al. 2007).
Bone marrow mononuclear cells
The major stem cell type in the bone marrow (BM) is
the hematopoietic stem cell (HSC). HSCs comprise less
than 0.1% of unfractionated bone marrow mononuclear
cell (BMMNC) samples (Challen et al. 2010). Although
the vast majority of BMMNCs are not stem cells, they
are still considered a significant source of hematopoietic
progenitors which may be useful for cardiac repair. In
2001, a landmark murine study administered BM- de-
rived HSCs by direct intramyocardial injection into
infarcted murine hearts (Orlic et al. 2001). The trans-
planted cells reportedly underwent transdifferentiation
directly into cardiomyocytes and supporting vasculature
leading to improved LV function. These results were
wholeheartedly embraced by clinicians and a wave of
clinical trials using BMMNCs for cardiac regeneration
ensued. The first of these reports using BM cardiac cell
therapy appeared only months after this initial murine
publication (Strauer et al. 2001) which proved to be
highly controversial. Several high profile groups have
been unable to replicate its findings (Murry et al. 2004;
Balsam et al. 2004). It is now generally believed that
transdifferentiation of HSCs to cardiomyocytes does not
occur to any meaningful degree. Importantly however,
cardiac cell therapy with BMMNCs may rely on other
mechanisms to achieve favorable cardiac repair after MI.
This may include secretion of growth factors and other
proteins capable of promoting angiogenesis (Ruger et al.
2008) and endogenous cardiac stem cell or cardiomyo-
cyte proliferation (Laflamme and Murry 2011).
Clinical trials using BMMNCs for cardiac repair have
now been the subject of several meta-analyses (Abdel-
Latif et al. 2007; Martin-Rendon et al. 2008; Clifford
et al. 2012). Together, close to 2000 subjects have re-
ceived BMMNCs as cell therapy for cardiac dysfunction
(predominantly for ischemic cardiomyopathy). The
pooled results suggest that this treatment appears safebut clinical improvements are modest. In fact, the very
recent phase 2 FOCUS-CCTRN trial reported no signifi-
cant improvement in LV end-systolic volume, further
undermining the efficacy of BMMNCs (Perin et al.
2012). Notably, most of the earlier trials used endpoints
based on LV functional imaging or subjective symptom
based questionnaires. No study has definitively examined
hard clinical endpoints such as mortality. To this end, a
large randomized multi-center European clinical trial in-
vestigating intracoronary delivery of BMMNCs after MI
has commenced enrolment with its primary endpoint
being all-cause mortality (NCT01569178) (Table 1). If
results are positive, this may lead to increased uptake of
this novel treatment by clinical cardiologists.
Mesenchymal stem cells
In addition to HSCs, mesenchymal stem cells (MSCs) rep-
resent another group of stem cells found in the BM, as
well as other tissues such as adipose tissue and cord blood.
MSCs (also known as mesenchymal stromal cells or
colony-forming unit fibroblasts) were first isolated over
40 years ago (Friedenstein et al. 1970) and have been
shown to directly transdifferentiate into cardiomyocytes in
the presence of the demethylating agent 5-azacytidine (5-
AZA) (Wakitani et al. 1995) or when co-cultured with
other cardiomyocytes (Rangappa et al. 2003; Li et al.
2007). Furthermore, MSCs possess several inherent fea-
tures which facilitate their use in a clinical setting. In
addition to being easily harvested and cultured ex vivo,
MSCs are believed to be able to modulate the host im-
mune system via lymphocyte regulation (Di Nicola et al.
2002) and the suppression of inflammatory cytokine re-
lease from cells of the innate immune system (Aggarwal
and Pittenger 2005). These characteristics render MSCs a
promising allogeneic cell source for treatment of infarcted
hearts.
As with BMMNCs however, controversy surrounds
their cardiomyogenic potential. In a study by Rose et al.,
BM-derived MSCs (BM-MSCs) did not transdifferentiate
into functional cardiomyocytes in vitro (Rose et al. 2008)
but were able to express cardiomyocyte specific proteins.
Regardless, MSCs remain the subject of considerable
interest for cardiac repair strategies. They rapidly pro-
gressed through the pre-clinical arena, where small and
large animal studies suggested potential to improve car-
diac function after induced MI (Shake et al. 2002; Schuleri
et al. 2009). Eventually clinical trials ensued. The first
of these was a randomized, double blinded, placebo
controlled phase 1 dose escalation study using intraven-
ous allogeneic BM-MSC infusions after MI (Hare et al.
2009). Here, MSC treatment appeared safe after twelve
months of follow up. Unexpectedly, when addressing
the arrhythmogenic potential of MSC transfusions, ambula-
tory electrocardiogram monitoring showed that arrhythmic
Table 1 Recent and ongoing clinical trials involving extra-cardiac stem cells in patients with ischemic cardiomyopathy
Trial name/Investigator Study
identifier
Comparators Endpoint Patients Delivery route Type classification
SKMs
MARVEL NCT00526253 Low dose vs high dose vs placebo Safety + QOL 170 Intramyocardial Safety + efficacy,
Phase 1/2
BMCs
REPAIR-AMI* NCT00279175 BMC vs placebo LVEF 204 Intracoronary Efficacy, Phase 3






BAMI NCT01569178 BMC vs no intervention All-cause
mortality
3000 Intramyocardial Safety + efficacy,
Phase 3
REPEAT NCT01693042 Single vs repeated (2 times) BMC infusions Mortality +
morbidity
676 Intracoronary Safety + efficacy,
Phase 2/3
FOCUS* NCT00824005 BMMNC vs placebo LVESV 92 Intramyocardial Safety + efficacy,
Phase 2
ASSURANCE NCT00869024 BMMNCs infusion Mortality +
morbidity
24 Intramyocardial Safety, Phase 1/2
REVITALIZE NCT00874354 BMMNCs infusion LVEF 30 Intracoronary Safety + efficacy,
Phase 1
EPCs/CD133+ Cells
PERFECT* NCT00950274 CD133+ vs placebo LVEF 142 Intramyocardial Efficacy, Phase 3
Cardio133* NCT00462774 CD133+ vs placebo LVEF 60 Intramyocardial Efficacy, Phase 2/3
IMPACT-CABG NCT01033617 CD133+ vs placebo SAE 20 Intramyocardial Safety + efficacy,
Phase 2
AlsterMACS NCT01337011 Intracoronary vs intramyocardial CD133+ infusions LVEF 64 Intracoronary/
Intramyocardial
Efficacy, Phase 1/2
SELECT-AMI NCT00529932 CD133+ vs placebo LV wall thickness 60 Intracoronary Safety + efficacy
EPCs/CD133+ Cells vs BMCs
Baharvand et al. NCT01167751 BMMNC vs CD133+ vs placebo infusions LVEF 105 Intracoronary Safety + efficacy,
Phase 3




ATHENA NCT01556022 MSCs vs placebo SAE + LVEF 45 Intramyocardial Safety + efficacy,
Phase 2


















Table 1 Recent and ongoing clinical trials involving extra-cardiac stem cells in patients with ischemic cardiomyopathy (Continued)
Parcero et al. NCT01502514 MSCs infusion QOL 10 Intramyocardial Safety + efficacy,
Phase 1/2
Umbilical Cord MSCs
Yan et al. NCT01946048 MSCs vs placebo LVEF 10 Intramyocardial Safety + efficacy,
Phase 1
Bone Marrow MSCs
ESTIMATION NCT01394432 MSCs vs placebo LVESV 50 Intramyocardial Efficacy, Phase 3
SEED-MSC NCT01392105 MSCs vs no intervention LVEF 80 Intracoronary Safety + efficacy,
Phase 2/3
Anastasiadis et al. NCT01753440 Allogeneic MSCs LVEF 30 Intramyocardial Safety + efficacy,
Phase 2/3
Anastasiadis et al. NCT01759212 Allogeneic MSCs LVF 10 Intramyocardial Safety + efficacy,
Phase 2/3
Perin et al. NCT00555828 25 vs 75 vs 150 million allogeneic MSCs vs placebo Safety + LVF 25 Intramyocardial Safety + efficacy,
Phase 1/2
PROMETHEUS* NCT00587990 Low vs high dose MSCs vs placebo SAE 45 Intramyocardial Safety + efficacy,
Phase 1/2
MESAMI NCT01076920 MSCs infusion Safety + LVF 10 Intramyocardial Safety, Phase 1/2




POSEIDON-Pilot* NCT01087996 Auto-MSCs (20, 100 or 200 million) vs Allo-MSCs (20, 100 or 200
million)
SAE + LVF 30 Intramyocardial Safety + efficacy,
Phase 1/2
BMCs vs MSCs
TAC-HFT* NCT00768066 MSCs (100 or 200 million) vs BMCs (100 or 200 million) vs placebo SAE + LVF 67 Intramyocardial Safety + efficacy,
Phase 1/2
All trials use autologous infusions unless otherwise stated. BMC-Bone Marrow Stem Cell, BMMNC-Bone Marrow Mononuclear Cell, EPC-Endothelial Progenitor Cell, G-CSF-Granulocyte-Colony Stimulating Factor, LVEF-
Left Ventricular Ejection Fraction, LVESV-Left Ventricular End Systolic Volume, LVF-Left Ventricular Function, MSC-Mesenchymal Stem Cell, QOL-Quality of Life, SAE-Serious Adverse Events, SKM-Skeletal Myoblast.
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an improvement in the global symptom score at 6 months
and a significant improvement in LV function at 3 but not
6 months. The latter finding was attributed to a “catch-up”
phenomenon in ventricular function of placebo treated
patients. Interestingly, similar “catch-up” has been re-
ported in BMMNC therapy trials (Meyer et al. 2006).
Recent trials also appear to support MSC derived im-
provements on cardiac dysfunction Table 1. The phase 1/2
randomized POSEIDON trial investigated autologous com-
pared to allogeneic MSCs in patients undergoing coronary
artery bypass grafting for ischemic cardiomyopathy. Initial
published results documented safety and overall efficacy
(Hare et al. 2012). Interestingly, further analysis of imaging
data found that the functional effects of MSCs appeared
preferentially at local sites of MSC injection whilst scar
reduction was seen more globally (Suncion et al. 2014).
Similar effects of MSCs on scar were seen by Williams
et al. who used percutaneous transendocardial injections
(Williams et al. 2011). The Transendocardial Autologous
Cells in Ischemic Heart Failure Trial (TAC-HFT) also
used percutaneous intramycoardial injections to com-
pare efficacy of MSCs to BMMNCs (Heldman et al.
2014). MSCs, but not BMMNCs, reduced infarct size
and improved regional myocardial function. The Pro-
spective Randomized Study of MSC Therapy in Patients
Undergoing Cardiac Surgery (PROMETHEUS) study used
magnetic resonance imaging to investigate mechanisms by
which MSCs may improve LV function (albeit in a very
limited sample population of six patients) (Karantalis et al.
2014). Myocardial segments injected with MSCs showed
not only a reduction in scar size with corresponding in-
creased contractile improvement, but also increased per-
fusion despite the lack of coronary artery bypass to these
segments.
A different and novel approach was used in the re-
cent C-CURE trial. Here the therapeutic effect of BM-
MSCs exposed to a cytokine cocktail designed to induce
partial cardiogenic differentiation was investigated (result-
ing cells were named cardiopoietic stem cells) (Bartunek
et al. 2013). The autologous cardiopoietic stem cells
were delivered via transendocardial injection into the
LV myocardium of patients suffering from an ische-
mic cardiomyopathy. Results showed that this strat-
egy was feasible and appeared safe. Furthermore, LV
function was significantly improved in the cardio-
poietic stem cell therapy group compared to placebo
(Bartunek et al. 2013).
It is important to note that the mechanisms underpinning
effects of MSC cardiac therapy are not yet completely
understood. Inconsistent pre-clinical results demonstrating
MSC differentiation into cardiomyocytes may be attributed
to varied methods of MSC isolation and propagation. Sig-
nificant MSC to cardiomyocyte transdifferentiation in theclinical trials discussed above seems unlikely since MSCs
engraft poorly in cardiac tissue. Theories have now shifted
to support a more indirect mechanism involving paracrine
mediators that in turn contribute to angiogenesis or new
host cardiomyocyte formation (either from resident cardiac
stem cells or division of existing cardiomyocytes) (Williams
et al. 2011, 2013; Li et al. 2010) (Figure 1).
Regarding origins, MSCs have reportedly been isolated
from virtually all post-natal organs (da Silva Meirelles
et al. 2006), including the heart (Chong et al. 2011,
2013). In particular, adipose tissue derived MSCs (AD-
MSCs) have become the subject of recent research ef-
forts. In preclinical rodent and porcine studies, these
MSCs were shown to induce angiogenesis and signifi-
cantly improve LV function (Valina et al. 2007; Cai et al.
2009). As a result, several clinical trials using AD-MSCs
are currently being conducted (Table 1).
Endothelial progenitor cells
Early reports of another stem/progenitor cell population
surfaced in 1997, when Asahara et al. described a popula-
tion of BM-derived cells expressing CD34 (HSC marker)
(Asahara et al. 1997). Notably, CD34 is also expressed in a
subset of endothelial cells. These cells were distinct from
other BM-derived stem cell populations and were named
endothelial progenitor cells (EPCs) due to their ability to
differentiate ex vivo towards an endothelial cell lineage.
Although expressing the cell surface proteins VEGFR2
and CD133 (Asahara et al. 1997; Yin et al. 1997), these
markers are ubiquitously expressed, and hence EPCs lack
a definitive marker for prospective identification and re-
quire in vitro assays for isolation and propagation.
The cardiac repair ability of EPCs lies in their potential
to promote neovascularization, possibly by both direct
(by differentiation into endothelial cells) and indirect
(mediated by angiogenic growth factors) mechanisms.
They are implicated in wound healing throughout the
body. For this reason, these cells continue to be studied
and may contribute clinically to cardiac repair post-MI
as well as to angiogenesis in patients with refractory an-
gina (Friis et al. 2011). This is the focus of a currently
recruiting phase 3 clinical trial called Efficacy and Safety
of Targeted Intramyocardial Delivery of Auto CD34+
Stem Cells for Improving Exercise Capacity in Subjects
With Refractory Angina (RENEW) (NCT01508910).
Pluripotent stem cells (embryonic stem cells/induced
pluripotent stem cells)
Embryonic stem cells (ESCs) extracted from the inner
cell mass of a blastocyst (early-stage embryo) are able to
give rise to cells of any of the 3 germ layers (Eckfeldt
et al. 2005). In the correct culture conditions, ESCs can
differentiate into many different cells from varied organs.
These cells thus possess formidable therapeutic potential
Figure 1 Schematic representation of the potential sequence of events involved in successful regenerative stem cell treatment of
cardiac tissue in an infarcted heart. BMMNC ‒ Bone Marrow Mononuclear Cell, CSC ‒ Cardiac Stem Cell, EPC ‒ Endothelial Progenitor Cell,
ESC ‒ Embryonic Stem Cell, ICM ‒ Inner Cell Mass, iPSC ‒ Induced Pluripotent Stem Cell, MSC ‒ Mesenchymal Stem Cell, SKM ‒ Skeletal Myoblast.
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cerns, however, have slowed their clinical translation.
Firstly, undifferentiated pluripotent stem cells harbor
great tumorigenic potential. Inadvertent transplantation
of these undifferentiated cells poses significant risks to
the receiving host. Secondly, ESCs will necessarily be
used as an allogeneic product which is likely to induce
host immune rejection following transplantation. Finally,
ethical concerns held by some groups have created polit-
ical hurdles in several countries. To some degree, the
limitations above have been addressed and clinical trials
using ESC-derived therapy have now become a reality
(Schwartz et al. 2012) (also see the ongoing ‘Safety Study
of GRNOPC1 in Spinal Cord Injury’ trial, NCT01217008).
With regards to cardiac therapy, several pre-clinical stud-
ies have demonstrated the ability of mouse (Min et al.
2002) and human (Laflamme et al. 2007; Fernandes et al.
2010; Pearl et al. 2011; Chong et al. 2014) ESC-derived
cardiomyocytes to engraft and repair the infarcted heart.
In 2006, a group led by Shinya Yamanaka reported the
possibility of reprogramming differentiated somatic cells
into a pluripotent state similar to ESCs (Takahashi andYamanaka 2006). These were named induced pluripotent
stem cells (iPSCs) and the initial murine studies were
replicated with human cells (Takahashi et al. 2007). This
method was embraced by scientists as a means to overcome
the ethical dilemmas associated with ESC use. Furthermore,
iPSCs could provide a theoretical means for a myriad of cell
types to be made from a recipient’s own somatic cells. The
resultant cell therapy products would be syngenic (genetic-
ally identical) and theoretically would circumvent the host’s
immune system. Nevertheless, T-cell mediated immune
rejection was evident in murine studies despite the use of
syngenic iPSCs (Zhao et al. 2011). In summary, pluripo-
tent stem cells bare undeniable potential for large scale
cardiac regeneration, but additional concerns must be ad-
dressed systematically to utilize their vast therapeutic abil-
ities. The interested reader is directed to the following
review covering recent translational efforts in this area
(Chong and Murry 2014).
Endogenous cardiac stem cells
The notion of the heart being a terminally differentiated
organ was first challenged almost a decade ago. Here,
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ous cardiac stem cells (CSCs) in the human adult heart
(Nadal-Ginard et al. 2003). In human sex-mismatched
cardiac transplants, female hearts transplanted into male
hosts had a significant number of chromosome Y positive
cardiomyocytes and coronary vessels expressing the stem
cell markers c-kit, mdr1 or Sca-1 (Quaini et al. 2002), sug-
gesting that the adult heart may not be quiescent as
previously thought. Since then, several cardiac stem cell
populations have been isolated from various species, in-
cluding humans. These populations possess the cardinal
characteristics of stem cells, namely long term self-renewal,
clonogenicity and multipotency, hence their regenerative
potential holds great promise for cardiac therapeutics. In
addition, it is expected that the restrictions in cardiomyo-
cyte differentiation of extra-cardiac adult stem cells arises
from epigenetic phenotypic restriction imposed on cells not
of cardiac origin. To this end, it is likely that CSCs have
greater potential for differentiation to cardiac cells, includ-
ing cardiomyocytes. Here we review the major cell popula-
tions thought to be endogenous cardiac stem cells.
Isl-1+ cardiac stem cells
Progenitor cells of the first and second heart fields in the
developing heart depend on cardiac-specific transcription
factors for their differentiation. Islet-1 (Isl-1) is a marker of
cardiac progenitors arising from the second heart field
(Klaus et al. 2012). Substantial work using murine models
of cardiogenesis have reported the progenitor phenotype of
this population (Laugwitz et al. 2005; Moretti et al. 2006).
Furthermore, in a report by Bu et al., transgenic and gene-
targeting approaches in human embryonic stem cell lines
demonstrated that purified Isl-1+ CSCs are pluripotent, re-
vealing their ability to form cardiomyocytes, endothelial
cells, vascular smooth muscle and cardiac conduction tis-
sue (Bu et al. 2009). This population of cells was proven to
be distinct from other CSC populations (c-kit, Sca-1 or
side-population cells ‒ see below) (Laugwitz et al. 2005).
c-kit + cardiac stem cells
c-kit is a tyrosine kinase surface receptor originally shown
to enrich for HSCs. It has now been used to identify stem
cell populations in other organs including the heart. Build-
ing on their previous study involving sex-mismatched car-
diac transplants in humans (Quaini et al. 2002), the same
laboratory proposing the presence of endogenous CSCs
was able to identify c-kit + CSCs in the hearts of dogs
(Linke et al. 2005), mice (Urbanek et al. 2005) and humans
(Bearzi et al. 2007). In rats, they found that c-kit + CSCs
formed new vasculature and immature myocytes when
injected into an infarcted heart (Beltrami et al. 2003), sub-
sequently improving cardiac function. The c-kit + CSCs
formed clusters in the interstitia between myocytes and
demonstrated signs of early cardiac myogenic differentiationevidenced by expression of the transcription factors Gata-
4, Nkx2-5 and Mef2c. Furthermore, after in vitro expan-
sion, these cells showed typical characteristics of stem
cells, including long term self-renewal, clonogenicity and
multipotency.
It is important to note that controversy surrounds the
myogenic potential of c-kit + CSCs. In a study by Zaruba
et al., the cardiomyogenic ability of c-kit + CSCs was high
in neonatal mice but decreased significantly with age and
was negligible by adulthood (Zaruba et al. 2010). These
findings are supported by other studies, including that by
Fazel et al., which also reported that c-kit + CSCs were ac-
tually of extra-cardiac origin (Fazel et al. 2006). Before in-
ducing MI in mice, Fazel et al. found that c-kit + cardiac
cells were rare (a finding also shared by others (Chong
et al. 2011; Beltrami et al. 2003)) and 1 month after MI,
none of the c-kit + cells were cardiomyocytes. They also
found that approximately 74% of c-kit + cardiac cells after
MI were in fact BM-derived. Contrasting these reports, a
recent transcriptional profiling study by Dey et al. reported
a clear difference in the molecular signatures of c-kit +
CSCs and c-kit + HSCs (Dey et al. 2013), suggesting differ-
ent origins and cell fates of BM and cardiac c-kit + cells.
Very recently, Berlo et al. used multiple rigorous fate map-
ping approaches in genetically modified mice to prove that
negligible cardiomyocyte contribution occurs from en-
dogenous cardiac c-kit + populations after normal ageing
or cardiac injury (van Berlo et al. 2014).
Despite the debate about c-kit + CSCs in preclinical
models, the Stem Cell Infusion in Patients with Ischemic
Cardiomyopathy (SCIPIO) phase 1 clinical trial proceeded
unabated and is currently ongoing (Bolli et al. 2011; Chugh
et al. 2012) (Table 2). In this trial, autologous c-kit + CSCs
were isolated and expanded ex vivo from patients undergo-
ing coronary artery bypass surgery after MI. Participants
were then randomized to receive either intracoronary infu-
sion of these c-kit + CSCs or conventional therapy. Prelim-
inary results of this study showed that isolation and
expansion of c-kit + CSCs in this manner was feasible and
that subsequent intracoronary delivery did not compromise
patient safety (Chugh et al. 2012). Furthermore, a signifi-
cant improvement in both global and regional LV function
and a reduction in infarct size were observed in the c-kit +
CSC group when compared to conventional therapy (Bolli
et al. 2011). It is
important to note that concerns regarding the integrity of
certain data generated during the trial have been raised by
the Lancet editors (The Lancet Editors 2014) and that con-
cerns regarding patient randomization have also been
raised (Nowbar et al. 2014).
Cardiosphere-derived cardiac stem cells
The term “cardiosphere” was first coined by Messina
et al. describing a population of undifferentiated cells,









ALLSTAR NCT01458405 Allogeneic CDCs vs placebo Infarct size 274 Intracoronary Safety + efficacy,
Phase 1/2
CADUCEUS* NCT00893360 CDCs (12.5 or 25 million) vs no
intervention
Safety 31 Intracoronary Safety, Phase 1
Cardiac Stem Cells + bFGF
ALCADIA* NCT00981006 CSCs + bFGF infusion Safety 6 Intramyocardial Safety, Phase 1
Cardiac Stem Cells
(undefined)
Vakilian et al. NCT01758406 CSCs vs placebo Mortality +
LVEF
50 Intracoronary Safety + efficacy,
Phase 2
SCIPIO* NCT00474461 CSCs infusion SAE 40 Intracoronary Safety + efficacy,
Phase 1
All trials use autologous infusions unless otherwise stated. Abbreviations: bFGF-Basic Fibroblast Growth Factor, CDCs-Cardiosphere-derived Cells, CSCs-Cardiac
Stem Cells, LVEF-Left Ventricular Ejection Fraction, SAE-Serious Adverse Events.
* Denotes trials with published results (including preliminary results).
Matar and Chong SpringerPlus 2014, 3:440 Page 8 of 14
http://www.springerplus.com/content/3/1/440isolated from cardiac biopsies and obtained by enzymatic
digestion of explanted cardiac tissue (Messina et al. 2004).
Cardiospheres (CSs) and cardiosphere-derived cells (CDCs)
have since been characterized as a heterogenous cell popu-
lation, containing a central core of c-kit + cells which are
surrounded by other cells including those expressing the
stromal cell marker CD105. In early preclinical work, CDCs
injected into infarcted murine hearts improved cardiac
function via apparent differentiation into both cardiomyo-
cytes and vasculature (Messina et al. 2004). Subsequently, a
more clinically applicable approach was devised for the iso-
lation and expansion of human CDCs from endomyocar-
dial biopsy specimens (Smith et al. 2007). The authors of
this study reported similar findings regarding the cardiac
regenerative potential of CDCs after engrafting the cells
into infarcted hearts of immunocompromised mice. Tech-
niques later used for the isolation and administration of hu-
man CDCs post-MI in clinical trials (see below) were
refined using a porcine model of myocardial ischemia/re-
perfusion (Johnston et al. 2009).
In contrast to the findings above, Andersen et al. used
novel culture methods to contest the cardiomyogenic
differentiation potential of human CSs (Andersen et al.
2009). They claimed that contamination with myocardial
tissue fragments is likely to be responsible for the ability
of CSs (isolated from neonatal rats) to spontaneously
contract. However, further studies (Davis et al. 2009,
2010) have refuted these results, thereby re-establishing
CDCs as a promising cardiac cell therapy candidate.
A recent study by Li et al. compared the functional
benefits of CDCs to those of enriched c-kit + CSCs, BM-
MNCs, BM-MSCs, and AD-MSCs (Li et al. 2012). They
found that CDCs had superior potency and myocardialrepair efficacy in murine models compared to the other
stem cell populations. This suggests that cell interactions
amongst the heterogenous CDC cell mix may be advan-
tageous. The model of allogeneic rather than autologous
CDC delivery in cardiac cell therapy has also been vali-
dated (Malliaras et al. 2012). This further expands their
prospective therapeutic potential by enabling an “off the
shelf” product.
In addition to c-kit + CSCs, CDCs are the only
other CSC to have published results from clinical tri-
als. CADUCEUS (Cardiosphere-Derived Autologous
Stem Cells to Reverse ventricular dysfunction) was a
prospective, randomized phase 1 trial assessing the
safety of autologous intracoronary CDC delivery in
patients post-MI (Makkar et al. 2012). Investigators
of this study utilized percutaneous techniques to ob-
tain endomyocardial biopsies from which CDCs were
isolated and expanded ex vivo. In a later procedure,
2–4 weeks after MI, the expanded CDCs were delivered by
intracoronary injection into the infarct-related arteries. Re-
sults from the CADUCEUS study show that CDC therapy
appears to be safe. Magnetic resonance imaging revealed that
at 3 months, CDC treatment reduced scar mass, increased
viable heart mass as well as increased regional systolic wall
thickening when compared to controls (Makkar et al. 2012).
Notably a statistically significant improvement in overall LV
function was not reported. Nevertheless, these results have
encouraged further investigation of allogeneic CDC therapy
in the larger ALLSTAR clinical trial (NCT01458405) (Table 2).
Side-population cardiac progenitors
The cardiac side-population (SP) represents a subpopula-
tion of cardiac progenitors possessing the unique ability to
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ferred by an ATP-binding cassette transporter (Unno et al.
2012). In humans, these protein transporters are encoded
by the ABCG2 gene, which can be used as a determinant
of the SP cell phenotype (Martin et al. 2004). SP cells com-
prise 4%, 2% and 1.2% of cells in the fetal, neonatal, and
adult rat heart, respectively (Leri et al. 2011). Initial
reports by Hierlihy et al. indicate that cardiac SP cells (C-
SPs) display stem cell activity, lack markers of differenti-
ated cell lineages, and possess significant cardiomyogenic
potential in vitro (Hierlihy et al. 2002). Confirming the
latter findings, Martin et al. found that C-SPs expressed
α-ACTININ (myocyte protein) when co-cultured with
cardiac main population cells (Martin et al. 2004), indi-
cating possible cardiomyocyte differentiation potential.
Similar to other CSC populations, the origin of C-SPs
has been questioned. To address a possible BM origin
for C-SPs, Mouquet et al. transplanted fluorescently la-
beled BM into wild-type adult mice (Mouquet et al.
2005) and investigated the effect of MI on these cells.
Injured hearts demonstrated an acute depletion of C-SPs
following MI, which was replenished (by up to 25%) by
fluorescently labeled BM-derived stem cells within
7 days. These cells then proceeded to adopt a C-SP
phenotype, suggesting that a significant portion of the
C-SP population is in fact BM-derived, rather than solely
of cardiac origin. Combining cell surface marker studies
with lineage tracing experiments will enable more accur-
ate tracking of C-SP origins and cell fates in vivo, allow-
ing for better characterization of their cardiac regenerative
abilities.
Sca-1+ cardiac stem cells
Stem cell antigen-1 (Sca-1) is widely used to enrich
HSCs in mice (Holmes and Stanford 2007). Humans lack
the murine Sca-1 gene and it is currently unknown
whether there is a true human orthologue. Sca-1+ CSCs
were first characterized in the adult murine myocardium
by Oh et al. as cardiac stem/progenitor cells lacking
hematopoietic lineage markers (Oh et al. 2003). Prior to
stimulation with 5-AZA, freshly isolated Sca-1+ CSCs
expressed the cardiogenic transcription factors Gata-4,
Mef2c and Tef-1. Upon stimulation, a small percentage
of these cells began to express cardiac structural genes
(sarcomeric α-actin, Tnni3, Nkx2-5, β-Mhc and α-Mhc)
and consequently acquired a phenotype resembling that of
cardiomyocytes. The authors reported that intraven-
ously delivered Sca-1+ CSCs home to sites of tissue in-
jury and form new cardiomyocytes in mice post-MI,
presenting a more clinically applicable view of their re-
generative potential.
Matsuura et al. subsequently demonstrated Sca-1+ CSC
multipotency by showing differentiation into osteocytes
and adipocytes (Matsuura et al. 2004). Furthermore, theydemonstrated that refined in vitro procedures using oxytocin
instead of 5-AZA to stimulate Sca-1+ CSC differentiation re-
sulted in the generation of spontaneously beating cardio-
myocytes. This added weight to the evidence supporting
the in vitro cardiac differentiation capacity of Sca-1+
CSCs. Further experimentation by Wang et al. revealed
that it is in fact the Sca-1+/CD31- sub-population that
possesses cardiomyogenic potential (Wang et al. 2006).
Notably, murine transgenic technology has provided
valuable insight into the molecular role of Sca-1+ CSCs.
Tateishi et al. demonstrated that knockdown of Sca-1
transcripts in CSCs led to retarded ex vivo expansion and
cell apoptosis (through Akt inactivation) (Tateishi et al.
2007). Their results also show that cardiomyocytes require
Sca-1 to upregulate secretion of paracrine effectors which
induce angiogenesis and limit cardiac apoptosis. This im-
plies that therapeutically, Sca-1 may promote CSC sur-
vival following engraftment into injured tissue and will in
turn influence revascularization and cardiac repair.
Epicardium derived cells
The epicardium is the outer layer of heart and inner layer
of the pericardium, consisting predominantly of mesothe-
lial cells and dense connective tissue. Epicardium-derived
cells (EPDCs) have long been known to play a fundamen-
tal role in the developing embryonic heart. Although these
cells were thought to be quiescent in healthy adult hearts,
recent evidence suggests that injury-associated signals
after MI induce reactivation of EPDCs, promoting heart
regeneration and injury reduction (Zhou et al. 2011). An-
other study has described this process as epithelial to mes-
enchymal transformation involving the migration of
multipotent EPDCs from the epicardium to the subepicar-
dial matrix, subsequently forming coronary vasculature
and cells of the cardiac interstitium (van Tuyn et al. 2007).
Paracrine mediators secreted by EPDCs have been shown
to underlie their regenerative potential (Zhou et al. 2011);
however, their direct contribution to the cardiomyocyte
and endothelial cell lineages remains controversial (Wes-
sels and Perez-Pomares 2004).
Smart et al. recently demonstrated that preconditioning
of adult murine hearts with thymosin β4 (crucial for neo-
vascularization of the neonatal heart), prior to infarction,
significantly activated the quiescent epicardium (Smart
et al. 2007). Activation led to EPDC mobilization and neo-
vascularization of the heart following MI, suggesting that
the adult mammalian epicardium harbors significant re-
generative potential. These recent studies highlight the
therapeutic potential of multipotent EPDCs found in the
postnatal mammalian heart.
Sca-1+/PDGFRα + cardiac stem cells
Amongst the various Sca-1+ subpopulations, a study
by Chong et al. identified a stem cell population that
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receptor α (PDGFRα) (Chong et al. 2011). By compre-
hensive lineage tracing experiments in genetic mouse
models, this CSC population was found to originate from
the embryonic epicardium (Chong et al. 2011) and exhib-
ited the cardinal features of stem cells (self-renewal,
clonogenicity and multipotency). Similar to BM-MSCs,
Sca-1+/PDGFRα +CSCs can form clonal colonies and
were therefore called cardiac colony-forming unit fibro-
lasts (cCFU-Fs). Recently, the same CSC population de-
scribed in these murine studies has been identified in
human hearts (Chong et al. 2013). It is likely that cCFU-Fs
contribute to the regenerative features observed in
EPDCs, but further verification is required to characterize
the extent and mechanism of their contribution to cardiac
regeneration of injured hearts.
Delivery
No agreement has been reached regarding the optimum
method of delivery of transplanted cells; intramyocardial
(IM), intravenous (IV) and intracoronary (IC) delivery
methods are all used interchangeably. The most clinic-
ally practiced form of cell delivery is the IC approach
which provides a direct route of cell delivery via coron-
ary arteries to myocardial sites of interest (Sheng et al.
2013). This procedure is normally carried out simultan-
eously during percutaneous coronary intervention post-
MI. Whilst being safe and efficient, 1 major limitation of
this procedure is that cells are not able to reach areas of
myocardium that are poorly perfused.
IV injections are only used selectively in patients fol-
lowing MI, as they rely on physiological homing sig-
nals from injured heart tissue, a state not present in
chronic heart failure. Although widely inefficient, IV
infusions are simple and minimally invasive. In con-
trast, transepicardial IM delivery is significantly inva-
sive but provides the most direct and precise delivery
method. Transendocardial IM delivery via percutan-
eous delivery catheters has been developed as possibly
the most efficient yet least invasive delivery method.
The AlsterMACS (Intracoronary Versus Intramyocar-
dial Application of Enriched CD133pos Autologous
Bone Marrow Derived Stem Cells) trial (NCT01337011)
compares 2 of the above delivery techniques, IC and
IM, in order to establish a universal mechanism for the
administration of stem cells to patients with ischemic
heart disease (Table 1). Another trial run by Vrtovec
et al. states through preliminary results that transendo-
cardial IM cell transplantation is associated with higher
retention rates and greater improvement in ventricular
function compared with IC administration (Vrtovec
et al. 2013) (NCT01350310).
In addition to conventional delivery methods, various
tissue engineering techniques provide novel approachesto improve sustainability and accuracy of cell culture
transplantation, augmenting the effects of transplanted
cells.Summary and prospects
The long held view of the human adult heart as a qui-
escent organ incapable of regeneration has only re-
cently been successfully challenged. It is now clear
that the heart possesses a small but significant ability
to regenerate after insults such as MI. Stem Cell ther-
apy can enhance this ability and may ultimately pro-
vide a viable clinical therapy to treat post-MI cardiac
dysfunction. However, considerable work remains.
Fore mostly, the best candidate cell type needs to be
elucidated. This will likely become clear with time. In
addition, the mechanisms underpinning favorable car-
diac effects of most, if not all of the stem cells
reviewed, are incompletely understood. Although not
a prerequisite for clinical therapy, mechanistic under-
standing will aid further refinement of cardiac cell
therapy and will speed effective clinical translation.
We strongly believe that cardiac regeneration, either
by delivery of extra-cardiac stem cells or by enhancing
endogenous mechanisms, will change the future of MI
treatment.
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